SC terms exorbitant drug pricing by pharma firms as 'extortion'

Prelims may ask: "Which constitutional article empowers SC to intervene in drug pricing?" or "Define extortion under IPC in pharma context." Mains could demand: "Analyze judicial activism in healthcare regulation and its constitutional implications" OR "Discuss whether price controls violate economic freedom under Article 19(1)(g)."

Tension between free market principles (Article 19(1)(g)) and right to health (Article 21). SC's use of harsh language ('extortion/dacoity') raises questions about judicial overreach vs. legitimate activism. Regulatory gap: whether DPCO (Drugs Price Control Order) adequately protects patients or if stronger statutory measures are needed.

Medicine pricing directly impacts India's healthcare accessibility and public health outcomes—critical for inclusive growth. This judgment signals SC's willingness to protect vulnerable citizens' constitutional right to life through aggressive pricing interventions, reshaping pharma-government-citizen dynamics.

• SC termed exorbitant drug pricing as 'extortion' and 'dacoity'—equating commercial practice with criminal acts • Right to Health (Article 21) vs. Commercial Freedom (Article 19) creates judicial tension in pricing regulation • DPCO's effectiveness and need for stricter regulatory oversight are key takeaways